BACKGROUND:Magnetic resonance imaging (MRI) in the CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction (CADUCEUS) trial revealed that cardiosphere-derived cells (CDCs) decrease scar size and increase viable myocardium after myocardial infarction (MI), but MRI has not been validated as an index of regeneration after cell therapy. We tested the validity of contrast-enhanced MRI in quantifying scarred and viable myocardium after cell therapy in a porcine model of convalescent MI. METHODS AND RESULTS:Yucatan minipigs underwent induction of MI and 2-3 weeks later were randomized to receive intracoronary infusion of 12.5×10(6) mismatched allogeneic CDCs or vehicle. Allogeneic CDCs induced mild local mononuclear infiltration but no systemic immunogenicity. MRI revealed that allogeneic CDCs attenuated remodeling, improved global and regional function, decreased scar size, and increased viable myocardium compared with placebo 2 months post-treatment. Extensive histological analysis validated quantitatively the MRI measurements of scar size, scar mass, and viable mass. CDCs neither altered gadolinium contrast myocardial kinetics nor induced changes in vascular density or architecture in viable and scarred myocardium. Histology demonstrated that CDCs lead to cardiomyocyte hyperplasia in the border zone, consistent with the observed stimulation of endogenous regenerative mechanisms (cardiomyocyte cycling, upregulation of endogenous progenitors, angiogenesis). CONCLUSIONS: Contrast-enhanced MRI accurately measures scarred and viable myocardium after cell therapy in a porcine model of convalescent MI. MRI represents a useful tool for assessing dynamic changes in the infarct and monitoring regenerative efficacy.
RCT Entities:
BACKGROUND: Magnetic resonance imaging (MRI) in the CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction (CADUCEUS) trial revealed that cardiosphere-derived cells (CDCs) decrease scar size and increase viable myocardium after myocardial infarction (MI), but MRI has not been validated as an index of regeneration after cell therapy. We tested the validity of contrast-enhanced MRI in quantifying scarred and viable myocardium after cell therapy in a porcine model of convalescent MI. METHODS AND RESULTS: Yucatan minipigs underwent induction of MI and 2-3 weeks later were randomized to receive intracoronary infusion of 12.5×10(6) mismatched allogeneic CDCs or vehicle. Allogeneic CDCs induced mild local mononuclear infiltration but no systemic immunogenicity. MRI revealed that allogeneic CDCs attenuated remodeling, improved global and regional function, decreased scar size, and increased viable myocardium compared with placebo 2 months post-treatment. Extensive histological analysis validated quantitatively the MRI measurements of scar size, scar mass, and viable mass. CDCs neither altered gadolinium contrast myocardial kinetics nor induced changes in vascular density or architecture in viable and scarred myocardium. Histology demonstrated that CDCs lead to cardiomyocyte hyperplasia in the border zone, consistent with the observed stimulation of endogenous regenerative mechanisms (cardiomyocyte cycling, upregulation of endogenous progenitors, angiogenesis). CONCLUSIONS: Contrast-enhanced MRI accurately measures scarred and viable myocardium after cell therapy in a porcine model of convalescent MI. MRI represents a useful tool for assessing dynamic changes in the infarct and monitoring regenerative efficacy.
Authors: Michael E Davis; J P Michael Motion; Daria A Narmoneva; Tomosaburo Takahashi; Daihiko Hakuno; Roger D Kamm; Shuguang Zhang; Richard T Lee Journal: Circulation Date: 2005-02-01 Impact factor: 29.690
Authors: O P Simonetti; R J Kim; D S Fieno; H B Hillenbrand; E Wu; J M Bundy; J P Finn; R M Judd Journal: Radiology Date: 2001-01 Impact factor: 11.105
Authors: R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: Anja Wagner; Heiko Mahrholdt; Louise Thomson; Stefan Hager; Gabriel Meinhardt; Wolfgang Rehwald; Michele Parker; Dipan Shah; Udo Sechtem; Raymond J Kim; Robert M Judd Journal: J Am Coll Cardiol Date: 2006-04-27 Impact factor: 24.094
Authors: Luciano C Amado; Bernhard L Gerber; Sandeep N Gupta; Dan W Rettmann; Gilberto Szarf; Robert Schock; Khurram Nasir; Dara L Kraitchman; João A C Lima Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Benjamin R Knowles; Philip G Batchelor; Victoria Parish; Matthew Ginks; Sven Plein; Reza Razavi; Tobias Schaeffter Journal: Magn Reson Med Date: 2008-12 Impact factor: 4.668
Authors: Christopher M Kramer; Jorg Barkhausen; Scott D Flamm; Raymond J Kim; Eike Nagel Journal: J Cardiovasc Magn Reson Date: 2008-07-07 Impact factor: 5.364
Authors: Jae Hyung Cho; Peter J Kilfoil; Rui Zhang; Ryan E Solymani; Catherine Bresee; Elliot M Kang; Kristin Luther; Russell G Rogers; Geoffrey de Couto; Joshua I Goldhaber; Eduardo Marbán; Eugenio Cingolani Journal: JCI Insight Date: 2018-10-04
Authors: Matthew C L Keith; Yukichi Tokita; Xian-Liang Tang; Shahab Ghafghazi; Joseph B Moore; Kyung U Hong; Julius B Elmore; Alok R Amraotkar; Haixun Guo; Brian L Ganzel; Kendra J Grubb; Michael P Flaherty; Bathri N Vajravelu; Marcin Wysoczynski; Roberto Bolli Journal: Basic Res Cardiol Date: 2015-07-07 Impact factor: 17.165